Literature DB >> 9486492

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.

Z S Pavletic1, S S Joshi, S J Pirruccello, S R Tarantolo, J Kollath, E C Reed, P J Bierman, J M Vose, P I Warkentin, T G Gross, K Nasrati, J O Armitage, A Kessinger, M R Bishop.   

Abstract

Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) >500/microl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8+ ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8+ cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9486492      PMCID: PMC7101861          DOI: 10.1038/sj.bmt.1701037

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  22 in total

1.  Significant mobilization of both conventional and regulatory T cells with AMD3100.

Authors:  Leslie S Kean; Sharon Sen; Olusegun Onabajo; Karnail Singh; Jennifer Robertson; Linda Stempora; Aylin C Bonifacino; Mark E Metzger; Daniel E L Promislow; Joseph J Mattapallil; Robert E Donahue
Journal:  Blood       Date:  2011-10-11       Impact factor: 22.113

Review 2.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party.

Authors:  M Simonin; A Dalissier; M Labopin; A Willasch; M Zecca; A Mouhab; A Chybicka; A Balduzzi; L Volin; C Peters; P Bader; J-H Dalle
Journal:  Bone Marrow Transplant       Date:  2017-04-10       Impact factor: 5.483

Review 4.  Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes.

Authors:  Laetitia Le Texier; Katie E Lineburg; Kelli P A MacDonald
Journal:  Int J Hematol       Date:  2016-12-10       Impact factor: 2.490

5.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Authors:  Yvonne Suessmuth; Rithun Mukherjee; Benjamin Watkins; Divya T Koura; Knut Finstermeier; Cindy Desmarais; Linda Stempora; John T Horan; Amelia Langston; Muna Qayed; Hanna J Khoury; Audrey Grizzle; Jennifer A Cheeseman; Jason A Conger; Jennifer Robertson; Aneesah Garrett; Allan D Kirk; Edmund K Waller; Bruce R Blazar; Aneesh K Mehta; Harlan S Robins; Leslie S Kean
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

6.  Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Ying Jiang; Roland Bassett; Gabriela Rondon; John McMannis; Marcos de Lima; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

7.  Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation.

Authors:  Romee Rizwan; John E Levine; Todd Defor; James L M Ferarra; Daniel J Weisdorf; Bruce R Blazar; Michael R Verneris
Journal:  Am J Hematol       Date:  2011-10       Impact factor: 10.047

8.  Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies.

Authors:  Michael J Burke; Rachel Isaksson Vogel; Sanyukta K Janardan; Claudio Brunstein; Angela R Smith; Jeffrey S Miller; Daniel Weisdorf; John E Wagner; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-08       Impact factor: 5.742

9.  Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods.

Authors:  Steven A Dezell; Yong-Oon Ahn; Jan Spanholtz; Hongbo Wang; Matthew Weeres; Scott Jackson; Sarah Cooley; Harry Dolstra; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-07       Impact factor: 5.742

10.  White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.

Authors:  Haesook T Kim; David Frederick; Philippe Armand; Emily Andler; Grace Kao; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Vincent T Ho
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.